clenbuterol has been researched along with Muscular Dystrophy, Animal in 9 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Muscular Dystrophy, Animal: MUSCULAR DYSTROPHY that occurs in VERTEBRATE animals.
Excerpt | Relevance | Reference |
---|---|---|
"Clenbuterol treatment significantly increased the relative mass (P<0." | 1.30 | Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol. ( Hayes, A; Williams, DA, 1998) |
"Clenbuterol treatment was associated with a 30-40% increase in fatigability in DIA and SOL muscles of control and mdx mice at both ages." | 1.29 | Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. ( Dupont-Versteegden, EE; Katz, MS; McCarter, RJ, 1995) |
"5." | 1.29 | Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. ( Hayes, A; Williams, DA, 1994) |
"Clenbuterol was given in the drinking water (1." | 1.29 | Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice. ( Dupont-Versteegden, EE, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 6 (66.67) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dupont-Versteegden, EE | 2 |
Katz, MS | 1 |
McCarter, RJ | 1 |
Hayes, A | 2 |
Williams, DA | 2 |
Zeman, RJ | 2 |
Zhang, Y | 1 |
Etlinger, JD | 2 |
Turner, PR | 1 |
Schultz, R | 1 |
Ganguly, B | 1 |
Steinhardt, RA | 1 |
Peng, H | 1 |
Danon, MJ | 1 |
Lynch, GS | 1 |
Hinkle, RT | 1 |
Faulkner, JA | 1 |
Rothwell, NJ | 1 |
Stock, MJ | 1 |
9 other studies available for clenbuterol and Muscular Dystrophy, Animal
Article | Year |
---|---|
Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice.
Topics: Animals; Clenbuterol; Diaphragm; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle Fatigue; Mus | 1995 |
Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice.
Topics: Animals; Body Weight; Clenbuterol; Dystrophin; Heart; Histocytochemistry; Isometric Contraction; Mal | 1994 |
Clenbuterol, a beta 2-agonist, retards wasting and loss of contractility in irradiated dystrophic mdx muscle.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Gamma Rays; Hindlimb; Male; Mice; Mice, Inbred mdx; | 1994 |
Proteolysis results in altered leak channel kinetics and elevated free calcium in mdx muscle.
Topics: Animals; Calcium; Calcium Channels; Calpain; Cells, Cultured; Clenbuterol; Dose-Response Relationshi | 1993 |
Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice.
Topics: Animals; Clenbuterol; Mice; Mice, Inbred mdx; Muscle Fatigue; Muscle, Skeletal; Muscular Dystrophy, | 1996 |
Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
Topics: Administration, Oral; Animals; Clenbuterol; Disease Models, Animal; Heart; Male; Mice; Mice, Mutant | 1998 |
Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle.
Topics: Adrenergic beta-Agonists; Aging; Animals; Clenbuterol; Humans; Mice; Mice, Inbred C57BL; Mice, Inbre | 2000 |
Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Clenbuterol; Energy Metabolism; In Vitro Techniques; | 2000 |
Modification of body composition by clenbuterol in normal and dystrophic (mdx) mice.
Topics: Animals; Body Composition; Body Weight; Clenbuterol; Energy Metabolism; Ethanolamines; Female; Mice; | 1985 |